View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Oct. 23, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Central Index Key	0000784199
Entity Registrant Name	CRYOLIFE INC
Trading Symbol	cry
Entity Common Stock, Shares Outstanding		33,457,552

Consolidated Statements Of Operations And Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Products	$ 27,029	$ 28,004	$ 84,519	$ 85,067
Preservation services	16,970	17,248	52,357	50,284
Total revenues	43,999	45,252	136,876	135,351
Cost of products and preservation services:
Products	6,220	6,598	21,196	21,299
Preservation services	7,917	8,872	23,401	26,348
Total cost of products and preservation services	14,137	15,470	44,597	47,647
Gross margin	29,862	29,782	92,279	87,704
Operating expenses:
General, administrative, and marketing	24,756	20,592	71,016	69,302
Research and development	4,277	3,714	13,098	9,602
Total operating expenses	29,033	24,306	84,114	78,904
Gain from sale of business components				(7,915)
Operating income	829	5,476	8,165	16,715
Interest expense	851	742	2,486	2,256
Interest income	(64)	(18)	(159)	(48)
Other expense (income), net	21	21	(70)	(146)
Income before income taxes	21	4,731	5,908	14,653
Income tax (benefit) expense	(1,304)	1,738	(803)	6,772
Net income	$ 1,325	$ 2,993	$ 6,711	$ 7,881
Income per common share:
Basic	$ 0.04	$ 0.09	$ 0.20	$ 0.24
Diluted	$ 0.04	$ 0.09	$ 0.19	$ 0.24
Weighted-average common shares outstanding:
Basic	32,887	32,151	32,665	31,731
Diluted	34,057	33,165	33,851	32,568
Other comprehensive income (loss)	$ 217	$ (31)	$ 582	$ (459)
Comprehensive income	$ 1,542	$ 2,962	$ 7,293	$ 7,422

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 54,242	$ 56,642
Restricted securities	771	699
Receivables, net	33,659	30,096
Inventories	27,763	26,293
Deferred preservation costs	35,008	30,688
Prepaid expenses and other	4,142	2,815
Total current assets	155,585	147,233
Property and equipment, net	20,607	18,502
Goodwill	78,294	78,294
Patents, net	827	1,008
Trademarks and other intangibles, net	62,454	65,633
Deferred income taxes	1,190
Investment in company owned life insurance	4,360	2,991
Other	2,823	2,479
Total assets	326,140	316,140
Current liabilities:
Accounts payable	5,066	5,744
Accrued expenses and other	17,813	19,796
Current portion of long-term debt	3,234	4,562
Total current liabilities	26,113	30,102
Long-term debt	64,835	67,012
Deferred compensation liability	3,753	2,600
Deferred rent obligations	2,982	2,355
Other	5,101	5,088
Total liabilities	102,784	107,157
Commitments and contingencies
Shareholders' equity:
Preferred stock
Common stock (issued shares of 34,844 in 2017 and 34,230 in 2016)	348	342
Additional paid-in capital	194,958	187,061
Retained earnings	40,616	34,143
Accumulated other comprehensive income (loss)	153	(429)
Treasury stock at cost (shares of 1,387 in 2017 and 1,356 in 2016)	(12,719)	(12,134)
Total shareholders' equity	223,356	208,983
Total liabilities and shareholders' equity	$ 326,140	$ 316,140

Consolidated Balance Sheets (Parenthetical) - shares shares in Thousands	Sep. 30, 2017	Dec. 31, 2016
Shareholders' equity:
Common stock, shares issued	34,844	34,230
Treasury stock at cost, shares	1,387	1,356

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net cash flows from operating activities:
Net income	$ 6,711	$ 7,881
Adjustments to reconcile net income to net cash from operating activities:
Gain from sale of business components		(7,915)
Depreciation and amortization	6,683	6,248
Non-cash compensation	5,652	4,617
Other non-cash adjustments to income	879	5,595
Changes in operating assets and liabilities:
Receivables	(4,303)	3,729
Inventories and deferred preservation costs	(6,901)	(5,739)
Prepaid expenses and other assets	(3,040)	(46)
Accounts payable, accrued expenses, and other liabilities	(855)	304
Net cash flows provided by operating activities	4,826	14,674
Net cash flows from investing activities:
Acquisition of On-X, net of cash acquired		(91,152)
Acquisition of PhotoFix technology		(1,226)
Proceeds from sale of business components	740	19,795
Decrease in restricted cash		5,000
Capital expenditures	(5,384)	(3,511)
Other	5	(12)
Net cash flows used in investing activities	(4,639)	(71,106)
Net cash flows from financing activities:
Proceeds from issuance of term loan		75,000
Repayment of term loan	(3,916)	(1,406)
Payment of debt issuance costs		(2,289)
Proceeds from exercise of stock options and issuance of common stock	2,599	2,116
Redemption and repurchase of stock to cover tax withholdings	(1,600)	(599)
Other	(3)	571
Net cash flows (used in) provided by financing activities	(2,920)	73,393
Effect of exchange rate changes on cash	333	(418)
(Decrease) increase in cash and cash equivalents	(2,400)	16,543
Cash and cash equivalents, beginning of period	56,642	37,588
Cash and cash equivalents, end of period	$ 54,242	$ 54,131

Basis Of Presentation	9 Months Ended
Basis Of Presentation	Sep. 30, 2017
Basis Of Presentation [Abstract]
Basis Of Presentation	1. Basis of Presentation Overview The accompanying summary consolidated financial statements include the accounts of CryoLife, Inc. and subsidiaries (“CryoLife,” the “Company,” “we,” or “us”). All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying Summary Consolidated Balance Sheet as of December 31, 2016 has been derived from audited financial statements. The accompanying unaudited summary consolidated financial statements as of, and for the three and nine months ended, September 30, 2017 and 2016 have been prepared in accordance with (i) accounting principles generally accepted in the U.S. for interim financial information and (ii) the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, such statements do not include all of the information and disclosures required by accounting principles generally accepted in the U.S. for a complete presentation of financial statements. In the opinion of management, all adjustments (including those of a normal, recurring nature) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. These summary consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in CryoLife’s Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on February 16, 2017. Change in Accounting for Employee Share-Based Payments As of January 1, 2017 we made an entity-wide accounting policy election in accordance with ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, (“ASU 2016-09”) to change our accounting policy to account for stock compensation forfeitures in the period awards are forfeited rather than estimating the effect of forfeitures. We elected to make this accounting policy change to simplify the accounting for share-based compensation and believe this method provides a more accurate reflection of periodic share-based compensation cost from the grant date forward. We used the modified retrospective transition method to record a net $238,000 cumulative-effect adjustment decrease to retained earnings for the accounting policy change, which included a $379,000 increase to additional paid-in capital and a $141,000 increase in deferred tax assets. Additionally, as of January 1, 2017 and in accordance with the guidance in ASU 2016-09, we made a change to account for excess tax benefits and deficiencies resulting from the settlement or vesting of share-based awards in income tax expense on our Summary Consolidated Statement of Operations and Comprehensive Income instead of accounting for these effects through additional paid in-capital on our Summary Consolidated Balance Sheets. We applied this amendment prospectively and prior periods have not been adjusted.

Financial Instruments

9 Months Ended

Sep. 30, 2017

Financial Instruments [Abstract]

Financial Instruments

2. Financial Instruments

The following is a summary of our financial instruments measured at fair value (in thousands):



September 30, 2017	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	371	$	--	$	--	$	371
Restricted securities:
Money market funds		771		--		--		771
Total assets	$	1,142	$	--	$	--	$	1,142


December 31, 2016	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	3,466	$	--	$	--	$	3,466
Restricted securities:
Money market funds		699		--		--		699
Total assets	$	4,165	$	--	$	--	$	4,165

We used prices quoted from our investment management companies to determine the Level 1 valuation of our investments in money market funds.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Cash Equivalents And Restricted Securities

9 Months Ended

Sep. 30, 2017

Cash Equivalents And Restricted Securities [Abstract]

Cash Equivalents And Restricted Securities

3. Cash Equivalents and Restricted Securities

The following is a summary of cash equivalents and restricted securities (in thousands):


			Unrealized		Estimated
			Holding		Market
September 30, 2017	Cost Basis		Gains		Value
Cash equivalents:
Money market funds	$	371	$	--	$	371
Restricted securities:
Money market funds		771		--		771

			Unrealized		Estimated
			Holding		Market
December 31, 2016	Cost Basis		Gains		Value
Cash equivalents:
Money market funds	$	3,466	$	--	$	3,466
Restricted securities:
Money market funds		699		--		699

As of September 30, 2017 and December 31, 2016 $771,000 and $699,000, respectively, of our money market funds were designated as short-term restricted securities due to a contractual commitment to hold the securities as pledged collateral relating primarily to international tax obligations.

There were no gross realized gains or losses on cash equivalents in the three and nine months ended September 30, 2017 and 2016. As of September 30, 2017 $235,000 of our restricted securities had a maturity date within three months and $536,000 had a maturity date between three months and one year. As of December 31, 2016 $490,000 of our restricted securities had a maturity date within three months and $209,000 had a maturity date between three months and one year.

Acquisition Of On-X Life Technologies

9 Months Ended

Sep. 30, 2017

Acquisition Of On-X Life Technologies [Abstract]

Acquisition Of On-X Life Technologies

4. Acquisition of On-X Life Technologies

Overview

On December 22, 2015 we entered into an agreement and plan of merger to acquire On-X Life Technologies Holdings, Inc. (“On-X”), an Austin, Texas-based, privately held mechanical heart valve company, for approximately $130.0 million, subject to certain adjustments. The transaction closed on January 20, 2016, and On-X is being operated as a wholly owned subsidiary of CryoLife.

The On-X catalogue of products includes the On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis. On-X also distributes CarbonAid CO₂ diffusion catheters and manufactures Chord-X ePTFE sutures for mitral chordal replacement. On-X also generates revenue from pyrolytic carbon coating products produced for other medical device manufacturers. We believe that the On-X products fit well into our product portfolio of medical devices for cardiac surgery and that we are capitalizing on the significant opportunity for CryoLife’s sales team to leverage their strong relationships with cardiac surgeons to introduce and to expand utilization of the On-X valves in the U.S. and internationally.

Accounting for the Transaction

The purchase price of the On-X transaction totaled $128.2 million, consisting of cash of $93.6 million and 3,703,699 shares of CryoLife common stock, with a value of $34.6 million as determined on the date of the closing. We recorded an allocation of the $128.2 million purchase price to On-X’s tangible and identifiable intangible assets acquired and liabilities assumed, based on their estimated fair values as of January 20, 2016. Goodwill was recorded based on the amount by which the purchase price exceeded the fair value of the net assets acquired and is not deductible for tax purposes. Goodwill from this transaction has been allocated to our Medical Devices segment.

The purchase price allocation is as follows (in thousands):


	Opening
	Balance Sheet
Cash and cash equivalents	$	2,472
Receivables		6,826
Inventories		12,889
Intangible assets		53,950
Goodwill		68,229
Other assets		6,891
Liabilities assumed		(23,040)
Total purchase price	$	128,217

We incurred transaction and integration costs of $7.4 million for the year ended December 31, 2016 related to the acquisition, which include, among other costs, expenses related to the termination of international and domestic distribution agreements. These costs were expensed as incurred and were primarily recorded as general, administrative, and marketing expenses on our Summary Consolidated Statements of Operations and Comprehensive Income.

We paid approximately $10 million of the purchase price into an escrow account upon closing of the On-X transaction. We are currently in litigation with the representative of the former On-X shareholders concerning the resolution of these escrow funds. We believe that we are entitled to recover the escrow funds and additional damages, but the outcome of litigation is inherently uncertain, and we may not recover any of the escrow funds.

Pro Forma Results

On-X revenues were $34.2 million from the date of acquisition through December 31, 2016. Our pro forma results of operations for the years ended December 31, 2016 and 2015, assuming the On-X acquisition had occurred as of January 1, 2015, are presented for comparative purposes below. These amounts are based on available information of the results of operations of On-X prior to the acquisition date and are not necessarily indicative of what the results of operations would have been had the acquisition been completed on January 1, 2015. This unaudited pro forma information does not project operating results post acquisition.

This pro forma information is as follows (in thousands, except per share amounts):


	Twelve Months Ended
	December 31,
	2016		2015
Total revenues	$	182,007	$	179,266
Net income (loss)		17,692		(4,787)

Pro forma income (loss) per common share - basic	$	0.54	$	(0.15)
Pro forma income (loss) per common share - diluted	$	0.53	$	(0.15)

Pro forma net income (loss) was calculated using a normalized tax rate of approximately 38%.

Sales Of Business Components	9 Months Ended
Sales Of Business Components	Sep. 30, 2017
Sales Of Business Components [Abstract]
Sales Of Business Components	5. Sale of Business Components Divestiture of the HeRO Graft Product Line On February 3, 2016 we sold our Hemodialysis Reliable Outflow Graft (“HeRO® Graft”) product line to Merit Medical Systems, Inc. (“Merit”) for $18.5 million in cash (“HeRO Sale”), of which $17.8 million was received on the transaction date and the remaining $740,000 was received in the first quarter of 2017. Under terms of the agreement, Merit acquired the HeRO Graft product line, including worldwide marketing rights, customer relationships, intellectual property, inventory, and certain property and equipment. We continued to manufacture the HeRO Graft under a transition supply agreement until the manufacturing transfer to Merit was completed in the second quarter of 2016. Sales prices under the transition supply agreement were at lower average prices than our previous sales to hospitals at end-user prices. The HeRO Graft product line was included as part of our Medical Devices segment. We recorded a pre-tax gain of approximately $8.8 million on the HeRO Sale. ProCol Distribution Agreement and Divestiture of the ProCol Product Line In 2014 we acquired the exclusive worldwide distribution rights to ProCol® Vascular Bioprosthesis (“ProCol”) from Hancock Jaffe Laboratories, Inc. (“Hancock Jaffe”). In accordance with the terms of the agreement, we made payments to Hancock Jaffe totaling $3.4 million for which we obtained the right to receive a designated amount of ProCol inventory for resale. As of March 18, 2016 we had received $1.7 million in inventory. The remaining $1.7 million in prepayments for inventory not yet delivered to us were settled as part of the ProCol Sale, described below. On March 18, 2016 we sold our ProCol distribution rights and purchase option to LeMaitre Vascular, Inc. (“LeMaitre”) for $2.0 million in cash (“ProCol Sale”), all of which was received by March 31, 2016. Under the terms of the agreement, LeMaitre acquired the ProCol related assets, including inventory, customer lists, related marketing assets, and our purchase option to acquire ProCol. LeMaitre exercised the option to acquire ProCol from Hancock Jaffe. The ProCol product was included as part of our Medical Devices segment. We recorded a pre-tax loss of approximately $845,000 on the ProCol Sale. Disclosure of the HeRO Sale and the ProCol Sale Financial Accounting Standards Board ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, (“ASU 2014-08”) defines the criteria for reporting discontinued operations and requires additional disclosures about discontinued operations. The standard requires that an entity report a disposal as a discontinued operation only if the disposal represents a strategic shift in operations that has a major effect on our operations and financial results. In the first quarter of 2016 we completed and recorded the HeRO Sale and the ProCol Sale and received cash for these transactions. Therefore, as of March 31, 2016 both transactions met the disposed of by sale criteria under ASU 2014-08. We evaluated the impact of the HeRO Sale and the ProCol Sale on our business to determine whether these disposals represent a strategic shift that has, or will have, a major effect on our financial position, results of operations, or cash flows. As the HeRO Graft and ProCol product lines combined represented less than 10% of our total revenues for the year ended December 31, 2015 and our total assets as of December 31, 2015, we believe that these transactions did not have a major effect on our operations and financial condition, either individually or in the aggregate, and therefore, we did not disclose these transactions as discontinued operations. The combined net gain from the HeRO Sale and ProCol Sale was therefore reported as gain from sale of business components on our Summary Consolidated Statements of Operations and Comprehensive Income.

PhotoFix Distribution Agreement And Acquisition	9 Months Ended
PhotoFix Distribution Agreement And Acquisition	Sep. 30, 2017
PhotoFix Distribution Agreement And Acquisition [Abstract]
PhotoFix Distribution Agreement And Acquisition	6. PhotoFix Distribution Agreement and Acquisition Overview In 2014 we entered into an exclusive supply and distribution agreement with Genesee Biomedical, Inc. (“GBI”) to acquire the distribution rights to PhotoFixTM, a bovine pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. PhotoFix has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance and is indicated for use in intracardiac repair, including ventricular repair and atrial repair, great vessel repair and suture line buttressing, and pericardial closure. We believe that PhotoFix fits well into our product portfolio of medical devices for cardiac surgery. In January 2015 we received our initial shipments and launched our distribution of PhotoFix. The agreement between CryoLife and GBI (the “GBI Agreement”) had an initial five-year term and was renewable for two one-year periods at our option. Under the terms of the GBI Agreement, we purchased PhotoFix inventory for resale at an agreed upon transfer price and had the option, which became effective in March 2015, to acquire the PhotoFix product line from GBI. Accounting for the Transaction On April 13, 2016 we exercised our right to acquire the PhotoFix technology from GBI for approximately $2.3 million, of which $1.2 million was paid in cash at closing, approximately $600,000 was previously provided to GBI as an advance under the distribution agreement, and approximately $400,000 is payable to GBI within 18 months of signing or earlier, subject to certain conditions. Our allocation of the purchase price to the tangible and identifiable intangible assets acquired, based on their estimated fair values, resulted in the allocation of the majority of the purchase price to amortizable intangible assets. GBI will continue to manufacture PhotoFix until we are able to fully establish manufacturing operations which is expected to occur in 2018.

Inventories And Deferred Preservation Costs

9 Months Ended

Sep. 30, 2017

Inventories And Deferred Preservation Costs [Abstract]

Inventories And Deferred Preservation Costs

7. Inventories and Deferred Preservation Costs

Inventories at September 30, 2017 and December 31, 2016 are comprised of the following (in thousands):


	September 30,		December 31,
	2017		2016
Raw materials and supplies	$	11,153	$	9,321
Work-in-process		4,028		3,321
Finished goods		12,582		13,651
Total inventories	$	27,763	$	26,293

Deferred preservation costs at September 30, 2017 and December 31, 2016 are comprised of the following (in thousands):


	September 30,		December 31,
	2017		2016
Cardiac tissues	$	17,195	$	15,768
Vascular tissues		17,813		14,920
Total deferred preservation costs	$	35,008	$	30,688

We maintain consignment inventory, included in finished goods inventories, of our On-X heart valves at domestic and foreign hospital locations to facilitate usage. We retain title to this consignment inventory until the valve is implanted, at which time we invoice the hospital. As of September 30, 2017 we had $5.8 million in consignment inventory, with approximately 85% in domestic locations and 15% in foreign locations. As of December 31, 2016 we had $4.9 million in consignment inventory with approximately 80% in domestic locations and 20% in foreign locations.

Goodwill And Other Intangible Assets

9 Months Ended

Sep. 30, 2017

Goodwill And Other Intangible Assets [Abstract]

Goodwill And Other Intangible Assets

8. Goodwill and Other Intangible Assets

Indefinite Lived Intangible Assets

As of September 30, 2017 and December 31, 2016 the carrying values of our indefinite lived intangible assets are as follows (in thousands):


	September 30,		December 31,
	2017		2016
Goodwill	$	78,294	$	78,294
Procurement contracts and agreements		2,013		2,013
Trademarks		841		841

Based on our experience with similar agreements, we believe that our acquired procurement contracts and agreements have indefinite useful lives, as we expect to continue to renew these contracts for the foreseeable future. We believe that our trademarks have indefinite useful lives as we currently anticipate that our trademarks will contribute to our cash flows indefinitely.

As of September 30, 2017 and December 31, 2016 our entire goodwill balance is related to our Medical Devices segment and there has been no change from the balance recorded as of December 31, 2016.

Definite Lived Intangible Assets

As of September 30, 2017 and December 31, 2016 the gross carrying values, accumulated amortization, and approximate amortization period of our definite lived intangible assets are as follows (in thousands):


	Gross Carrying		Accumulated		Amortization
September 30, 2017	Value		Amortization		Period
Acquired technology	$	38,478	$	7,615	11	–	22	Years
Patents		3,593		2,766			17	Years
Distribution and manufacturing rights and know-how		4,059		1,748	11	–	15	Years
Customer lists and relationships		29,140		3,190	13	–	22	Years
Other		1,418		942			3	Years

	Gross Carrying		Accumulated		Amortization
December 31, 2016	Value		Amortization		Period
Acquired technology	$	38,478	$	5,956	11	–	22	Years
Patents		3,710		2,702			17	Years
Distribution and manufacturing rights and know-how		4,059		1,532	11	–	15	Years
Customer lists and relationships		29,140		2,141	13	–	22	Years
Non-compete agreement		381		381			10	Years
Other		1,262		531			3	Years

Amortization Expense

The following is a summary of amortization expense as recorded in general, administrative, and marketing expenses on our Summary Consolidated Statement of Operations and Comprehensive Income (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Amortization expense	$	1,140	$	1,155	$	3,423	$	3,273

As of September 30, 2017 scheduled amortization of intangible assets for the next five years is as follows (in thousands):


	Remainder
	of 2017		2018		2019		2020		2021		2022
Amortization expense	$	1,140	$	4,444	$	4,102	$	3,939	$	3,918	$	3,390

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2017
Income Taxes [Abstract]
Income Taxes	9. Income Taxes Income Tax Expense Our income tax rate for the three and nine months ended September 30, 2017 was favorably affected by excess tax benefits, primarily related to the exercise of non-qualified stock options and the vesting of stock awards, as discussed in Note 1 above, which decreased income tax expense by approximately $1.1 million and $2.7 million, respectively. Our effective income tax rate was 37% and 46% for the three and nine months ended September 30, 2016, respectively. Our income tax rate for the three and nine months ended September 30, 2016 was unfavorably impacted by the tax treatment of certain expenses related to the On-X acquisition, which had a larger impact on the tax rate in first quarter of 2016. Our income tax rate for the nine months ended September 30, 2016 was also unfavorably impacted by book/tax basis differences related to the HeRO Sale. Deferred Income Taxes We generate deferred tax assets primarily as a result of write-downs of inventory and deferred preservation costs; accruals for product and tissue processing liability claims; investment and asset impairments; and, in prior periods, due to operating losses. We acquired significant deferred tax assets, primarily net operating loss carryforwards, from our acquisitions of On-X in 2016, Hemosphere in 2012, and Cardiogenesis in 2011. We recorded significant deferred tax liabilities in 2016 related to the intangible assets acquired in the On-X acquisition. As of September 30, 2017 we maintained a total of $1.8 million in valuation allowances against deferred tax assets, related to state net operating loss carryforwards, and had a net deferred tax asset of $1.2 million. As of December 31, 2016 we had a total of $2.2 million in valuation allowances against deferred tax assets, related to state net operating loss carryforwards, and a net deferred tax liability of $7,000.

Debt

9 Months Ended

Sep. 30, 2017

Debt [Abstract]

Debt

10. Debt

Amended Debt Agreement

In connection with the closing of the On-X acquisition, discussed above in Note 4, on January 20, 2016, CryoLife and certain of our subsidiaries entered into the Third Amended and Restated Credit Agreement (“Amended Debt Agreement”) with Capital One, National Association, who acquired GE Capital’s Healthcare Financial Services lending business in late 2015. The designated credit parties are Healthcare Financial Solutions, LLC; Fifth Third Bank; and Citizens Bank, National Association. The Amended Debt Agreement amended and restated our prior credit agreement and provides us with a senior secured credit facility in an aggregate principal amount of $95 million, which includes a $75 million term loan and a $20 million revolving credit facility (including a $4 million letter of credit sub-facility and a $3 million swing-line sub-facility). The $75 million term loan was used to finance, in part, the acquisition of On-X and will mature on January 20, 2021.

CryoLife and our domestic subsidiaries, subject to certain exceptions and exclusions, have guaranteed the obligations of the Amended Debt Agreement. Borrowings under the Amended Debt Agreement are secured by substantially all of CryoLife’s, and certain of our subsidiaries’, real and personal property.

The loans under the Amended Debt Agreement (other than the swing-line loans) bear interest, at our option, at either a floating rate equal to the base rate, as defined in the Amended Debt Agreement, plus a margin of between 1.75% and 2.75%, depending on our consolidated leverage ratio, or a per annum rate equal to LIBOR plus a margin of between 2.75% and 3.75%, depending on our consolidated leverage ratio. As of September 30, 2017 the aggregate interest rate was approximately 3.99%. Swing-line loans under the Amended Debt Agreement bear interest at a floating rate equal to the base rate plus a margin of between 1.75% and 2.75%, depending on our consolidated leverage ratio. We are obligated to pay an unused commitment fee equal to 0.50% of the un-utilized portion of the revolving loans. In addition, we are also obligated to pay other customary fees for a credit facility of this size and type. If and while a payment event of default exists, we are obligated to pay a per annum default rate of interest of 2.00% above the applicable interest rate on the past due principal amount of the loans outstanding. If and while a bankruptcy or insolvency event of default exists, we are obligated to pay a per annum default rate of interest of 2.00% above the applicable interest rate on all loans outstanding.

Interest is due and payable, with respect to base rate loans, on a quarterly basis. Interest is due and payable, with respect to LIBOR loans, on the last day of the applicable interest period, if the interest period is shorter than six months, or on the last day of each three month interval, if the interest period is six months or greater.

The Amended Debt Agreement prohibits us from exceeding a maximum consolidated leverage ratio during the term of the Amended Debt Agreement and requires us to maintain a minimum interest coverage ratio. In addition, the Amended Debt Agreement contains certain customary affirmative and negative covenants, including covenants that limit our ability and the ability of our subsidiaries which are parties to the loan agreement to, among other things, grant liens; incur debt; dispose of assets; make loans and investments; make acquisitions; make certain restricted payments; merge or consolidate; and change our business and accounting or reporting practices, in each case subject to customary exceptions for a credit facility of this size and type. As of October 31, 2017 CryoLife and our subsidiaries were in compliance with the covenants of the Amended Debt Agreement.

The Amended Debt Agreement includes certain customary events of default that include, among other things, non-payment of principal, interest or fees; inaccuracy of representations and warranties; violation of covenants; cross-default on certain other indebtedness; bankruptcy and insolvency; and change of control. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued but unpaid interest under the Amended Debt Agreement immediately due and payable, and may exercise the other rights and remedies provided for under the Amended Debt Agreement and related loan documents.

As of both September 30, 2017 and December 31, 2016 there were no outstanding balances on our revolving credit facility and the remaining availability was $20.0 million. The short-term and long-term balances of our term loan are as follows (in thousands):


	September 30,		December 31,
	2017		2016
Term loan balance	$	69,678	$	73,594
Less unamortized loan origination costs		(1,609)		(2,020)
Net borrowings		68,069		71,574
Less short-term loan balance		(3,234)		(4,562)
Long-term loan balance	$	64,835	$	67,012

Interest Expense

Interest expense was $851,000 and $2.5 million for the three and nine months ended September 30, 2017, respectively, and $742,000 and $2.3 million for the three and nine months ended September 30, 2016, respectively. Interest expense in 2017 and 2016 included interest on debt and uncertain tax positions.

Commitments And Contingencies	9 Months Ended
Commitments And Contingencies	Sep. 30, 2017
Commitments And Contingencies [Abstract]
Commitments And Contingencies	11. Commitments and Contingencies Liability Claims Our estimated unreported loss liability was $1.6 million as of September 30, 2017 and $1.5 million as of December 31, 2016. As of September 30, 2017 and December 31, 2016, the related recoverable insurance amounts were $716,000 and $626,000, respectively. We accrue our estimate of unreported product and tissue processing liability claims as a component of other long‑term liabilities and record the related recoverable insurance amount as a component of other long‑term assets, as appropriate. Further analysis indicated that the estimated liability as of September 30, 2017 could have been as high as $3.0 million, after including a reasonable margin for statistical fluctuations calculated based on actuarial simulation techniques. Employment Agreements The employment agreement of our Chairman, President, and Chief Executive Officer (“CEO”), Mr. J. Patrick Mackin, provides for a severance payment, which would become payable upon the occurrence of certain employment termination events, including termination by us without cause. PerClot Technology On September 28, 2010 we entered into a worldwide distribution agreement (the “Distribution Agreement”) and a license and manufacturing agreement (the “License Agreement”) with Starch Medical, Inc. (“SMI”), for PerClot, a polysaccharide hemostatic agent used in surgery. The Distribution Agreement has a term of 15 years, but can be terminated for any reason before the expiration date by us by providing 180 days’ notice. The Distribution Agreement also contains minimum purchase requirements that expire upon the termination of the Distribution Agreement or following U.S. regulatory approval for PerClot. Separate and apart from the terms of the Distribution Agreement, pursuant to the License Agreement, as amended by a September 2, 2011 technology transfer agreement, we can manufacture and sell PerClot, assuming appropriate regulatory approvals, in the U.S. and certain other jurisdictions and may be required to pay royalties to SMI at certain rates on net revenues of products. We may make contingent payments to SMI of up to $1.0 million if certain U.S. regulatory and certain commercial milestones are achieved. We are conducting our pivotal clinical trial to gain approval to commercialize PerClot for surgical indications in the U.S. We resumed enrollment into the trial in the fourth quarter of 2016 and, assuming enrollment proceeds as anticipated, we could receive Premarket Approval from the FDA in 2019. As of September 30, 2017 we had $1.5 million in prepaid royalties, $2.7 million in net intangible assets, and $1.4 million in property and equipment, net on our Summary Consolidated Balance Sheets related to the PerClot product line. If we do not ultimately pursue or receive FDA approval to commercialize PerClot in the U.S., these assets could be materially impaired in future periods.

Shareholders' Equity	9 Months Ended
Shareholders' Equity	Sep. 30, 2017
Shareholders' Equity [Abstract]
Shareholders' Equity	12. Shareholders’ Equity Change in Accounting for Employee Share-Based Payments As discussed in Note 1 above, as a result of the adoption of ASU 2016-09, we recorded a net $238,000 cumulative-effect adjustment decrease to retained earnings, which included a $379,000 increase to additional paid-in capital and a $141,000 increase in deferred tax assets. Common Shares Issued In January 2016 we issued 3,703,699 shares of CryoLife common stock, as part of the consideration for the acquisition of On-X. The stock had a value of $34.6 million as determined on the date of the closing. See Note 4 for further discussion of the On-X acquisition.

Stock Compensation

9 Months Ended

Sep. 30, 2017

Stock Compensation [Abstract]

Stock Compensation

13. Stock Compensation

Overview

We have stock option and stock incentive plans for employees and non-employee Directors that provide for grants of restricted stock awards (“RSAs”), performance stock awards (“PSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”), and options to purchase shares of our common stock at exercise prices generally equal to the fair value of such stock at the dates of grant. We also maintain a shareholder-approved Employee Stock Purchase Plan (the “ESPP”) for the benefit of our employees. The ESPP allows eligible employees to purchase common stock on a regular basis at the lower of 85% of the market price at the beginning or end of each offering period.

Equity Grants

During the nine months ended September 30, 2017 the Compensation Committee of our Board of Directors (the “Committee”) authorized awards from approved stock incentive plans of RSUs to certain employees and RSAs and PSUs to certain Company officers, which, assuming that performance under the PSUs were to be achieved at target levels, together totaled 384,000 shares and had an aggregate grant date market value of $6.3 million. The PSUs granted in 2017 represent the right to receive from 60% to 150% of the target number of shares of common stock. The performance component of PSU awards granted in 2017 is based on attaining specified levels of adjusted EBITDA, adjusted inventory levels, and trade accounts receivable days' sales outstanding, each as defined in the PSU grant documents, for the 2017 calendar year. We currently believe that achievement of the performance component is probable, and we reevaluate this likelihood on a quarterly basis.

During the nine months ended September 30, 2016 the Committee authorized awards from approved stock incentive plans of RSUs to certain employees and RSAs and PSUs to certain Company officers, which, including PSUs at target levels, together totaled 478,000 shares of common stock and had an aggregate grant date market value of $5.3 million. The PSUs granted in 2016 represented the right to receive from 60% to 150% of the target number of shares of common stock. The performance component of PSU awards granted in 2016 was based on attaining specified levels of adjusted EBITDA, adjusted inventory levels, and trade accounts receivable days’ sales outstanding, each as defined in the PSU grant documents, for the 2016 calendar year. The PSUs granted in 2016 earned 142% of the target number of shares.

The Committee authorized, from approved stock incentive plans, grants of stock options to purchase a total of 260,000 and 387,000 shares to certain Company officers during the nine months ended September 30, 2017 and 2016, respectively. The exercise prices of the options were equal to the closing stock prices on their respective grant dates.

Employees purchased common stock totaling 47,000 and 93,000 shares in the three and nine months ended September 30, 2017, respectively, and 52,000 and 90,000 shares in the three and nine months ended September 30, 2016, respectively, through the ESPP.

Stock Compensation Expense

The following weighted‑average assumptions were used to determine the fair value of options:


	Three Months Ended				Nine Months Ended
	September 30, 2017				September 30, 2017
	Stock Options		ESPP Options		Stock Options		ESPP Options
Expected life of options		N/A		0.5 Years		4.8 Years		0.5 Years
Expected stock price volatility		N/A		0.43		0.40		0.35
Risk-free interest rate		N/A		1.14%		1.87%		0.62%


	Three Months Ended				Nine Months Ended
	September 30, 2016				September 30, 2016
	Stock Options		ESPP Options		Stock Options		ESPP Options
Expected life of options		4.8 Years		0.5 Years		4.8 Years		0.5 Years
Expected stock price volatility		0.40		0.30		0.40		0.30
Risk-free interest rate		1.19%		0.49%		1.20%		0.49%

The following table summarizes total stock compensation expenses prior to the capitalization of amounts into deferred preservation and inventory costs (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
RSA, PSA, RSU, and PSU expense	$	1,448	$	1,397	$	4,326	$	3,616
Stock option and ESPP option expense		519		421		1,614		1,203
Total stock compensation expense	$	1,967	$	1,818	$	5,940	$	4,819

Included in the total stock compensation expense, as applicable in each period, were expenses related to RSAs, PSAs, RSUs, PSUs, and stock options issued in each respective year, as well as those issued in prior periods that continue to vest during the period, and compensation related to the ESPP. These amounts were recorded as stock compensation expense and were subject to our normal allocation of expenses to inventory costs and deferred preservation costs. We capitalized $111,000 and $288,000 in the three and nine months ended September 30, 2017, respectively, and $70,000 and $202,000 in the three and nine months ended September 30, 2016, respectively, of the stock compensation expense into our inventory costs and deferred preservation costs.

As of September 30, 2017 we had total unrecognized compensation costs of $6.8 million related to RSUs, RSAs, and PSUs and $2.1 million related to unvested stock options. As of September 30, 2017 this expense is expected to be recognized over a weighted-average period of 2.1 years for RSUs, 1.7 years for stock options, 1.3 years for RSAs, and 1.0 years for PSUs.

Income Per Common Share

9 Months Ended

Sep. 30, 2017

Income Per Common Share [Abstract]

Income Per Common Share

14. Income Per Common Share

The following table sets forth the computation of basic and diluted income per common share (in thousands, except per share data):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
Basic income per common share	2017		2016		2017		2016
Net income	$	1,325	$	2,993	$	6,711	$	7,881
Net income allocated to participating securities		(22)		(58)		(126)		(152)
Net income allocated to common shareholders	$	1,303	$	2,935	$	6,585	$	7,729

Basic weighted-average common shares outstanding		32,887		32,151		32,665		31,731
Basic income per common share	$	0.04	$	0.09	$	0.20	$	0.24

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
Diluted income per common share	2017		2016		2017		2016
Net income	$	1,325	$	2,993	$	6,711	$	7,881
Net income allocated to participating securities		(22)		(56)		(122)		(148)
Net income allocated to common shareholders	$	1,303	$	2,937	$	6,589	$	7,733

Basic weighted-average common shares outstanding		32,887		32,151		32,665		31,731
Effect of dilutive stock options and awardsa		1,170		1,014		1,186		837
Diluted weighted-average common shares outstanding		34,057		33,165		33,851		32,568
Diluted income per common share	$	0.04	$	0.09	$	0.19	$	0.24

___________________

aWe excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to income per common share. Accordingly, stock options to purchase a weighted-average 264,000 and 215,000 shares for the three and nine months ended September 30, 2017, respectively, and 1,000 and 810,000 shares for the three and nine months ended September 30, 2016, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.

Segment Information

9 Months Ended

Sep. 30, 2017

Segment Information [Abstract]

Segment Information

15. Segment Information

We have two reportable segments organized according to our products and services: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue® Surgical Adhesive; BioFoam® Surgical Matrix; On-X products, since the acquisition of On-X; CardioGenesis cardiac laser therapy; PerClot; PhotoFix; HeRO Graft, through the second quarter of 2016; and ProCol, through the date of the sale of the ProCol product line in the first quarter of 2016. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. There are no intersegment revenues.

The primary measure of segment performance, as viewed by our management, is segment gross margin, or net external revenues less cost of products and preservation services. We do not segregate assets by segment; therefore, asset information is excluded from the segment disclosures below.

The following table summarizes revenues, cost of products and preservation services, and gross margins for our operating segments (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Revenues:
Medical devices	$	27,029	$	28,004	$	84,519	$	85,067
Preservation services		16,970		17,248		52,357		50,284
Total revenues		43,999		45,252		136,876		135,351

Cost of products and preservation services:
Medical devices		6,220		6,598		21,196		21,299
Preservation services		7,917		8,872		23,401		26,348
Total cost of products and preservation services		14,137		15,470		44,597		47,647

Gross margin:
Medical devices		20,809		21,406		63,323		63,768
Preservation services		9,053		8,376		28,956		23,936
Total gross margin	$	29,862	$	29,782	$	92,279	$	87,704

The following table summarizes net revenues by product and service (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Products:
BioGlue and BioFoam	$	15,730	$	15,976	$	48,094	$	47,479
On-X		8,326		8,890		27,048		25,159
CardioGenesis cardiac laser therapy		1,489		1,653		5,130		5,497
PerClot		886		950		2,641		2,983
PhotoFix		598		535		1,606		1,406
HeRO Graft		--		--		--		2,325
ProCol		--		--		--		218
Total products		27,029		28,004		84,519		85,067

Preservation services:
Cardiac tissue		7,932		8,279		23,911		22,255
Vascular tissue		9,038		8,969		28,446		28,029
Total preservation services		16,970		17,248		52,357		50,284

Total revenues	$	43,999	$	45,252	$	136,876	$	135,351

JOTEC Acquisition	9 Months Ended
JOTEC Acquisition	Sep. 30, 2017
JOTEC Acquisition [Abstract]
JOTEC Acquisition	16. JOTEC Acquisition On October 10, 2017 we announced that we entered into a definitive agreement to acquire JOTEC AG (“JOTEC”). The transaction is expected to close later this year, subject to customary closing conditions. JOTEC is a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair. The combination of CryoLife and JOTEC will create a company with a broad and highly competitive product portfolio focused on aortic surgery, and will position us to compete strongly in the important and growing endovascular surgical markets. Under terms of the definitive agreement, we will acquire JOTEC for a purchase price of $225 million, subject to certain adjustments, consisting of 75% in cash and 25% in CryoLife common stock issued to JOTEC’s shareholders. We expect to finance the transaction and related expenses, as well as refinance our existing approximately $69 million term loan, with a new $255 million senior secured credit facility, consisting of a $225 million institutional term loan B and a $30 million undrawn revolving credit facility, $56.25 million in CryoLife common stock as determined on the date of signing of the agreement, and available cash on hand. The senior secured credit facility is fully underwritten by Deutsche Bank, Capital One and Fifth Third Bank and is expected to be syndicated to investors prior to closing of the acquisition.

Basis Of Presentation (Policy)	9 Months Ended
Basis Of Presentation (Policy)	Sep. 30, 2017
Basis Of Presentation [Abstract]
Change In Accounting For Employee Share-Based Payments	Change in Accounting for Employee Share-Based Payments As of January 1, 2017 we made an entity-wide accounting policy election in accordance with ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, (“ASU 2016-09”) to change our accounting policy to account for stock compensation forfeitures in the period awards are forfeited rather than estimating the effect of forfeitures. We elected to make this accounting policy change to simplify the accounting for share-based compensation and believe this method provides a more accurate reflection of periodic share-based compensation cost from the grant date forward. We used the modified retrospective transition method to record a net $238,000 cumulative-effect adjustment decrease to retained earnings for the accounting policy change, which included a $379,000 increase to additional paid-in capital and a $141,000 increase in deferred tax assets. Additionally, as of January 1, 2017 and in accordance with the guidance in ASU 2016-09, we made a change to account for excess tax benefits and deficiencies resulting from the settlement or vesting of share-based awards in income tax expense on our Summary Consolidated Statement of Operations and Comprehensive Income instead of accounting for these effects through additional paid in-capital on our Summary Consolidated Balance Sheets. We applied this amendment prospectively and prior periods have not been adjusted.

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2017

Financial Instruments [Abstract]

Summary Of Financial Instruments Measured At Fair Value



September 30, 2017	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	371	$	--	$	--	$	371
Restricted securities:
Money market funds		771		--		--		771
Total assets	$	1,142	$	--	$	--	$	1,142


December 31, 2016	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	3,466	$	--	$	--	$	3,466
Restricted securities:
Money market funds		699		--		--		699
Total assets	$	4,165	$	--	$	--	$	4,165

Cash Equivalents And Restricted Securities (Tables)

9 Months Ended

Sep. 30, 2017

Cash Equivalents And Restricted Securities [Abstract]

Summary Of Cash Equivalents And Restricted Securities


			Unrealized		Estimated
			Holding		Market
September 30, 2017	Cost Basis		Gains		Value
Cash equivalents:
Money market funds	$	371	$	--	$	371
Restricted securities:
Money market funds		771		--		771

			Unrealized		Estimated
			Holding		Market
December 31, 2016	Cost Basis		Gains		Value
Cash equivalents:
Money market funds	$	3,466	$	--	$	3,466
Restricted securities:
Money market funds		699		--		699

Acquisition Of On-X Life Technologies (Tables)

9 Months Ended

Sep. 30, 2017

Acquisition Of On-X Life Technologies [Abstract]

Purchase Price Allocation


	Opening
	Balance Sheet
Cash and cash equivalents	$	2,472
Receivables		6,826
Inventories		12,889
Intangible assets		53,950
Goodwill		68,229
Other assets		6,891
Liabilities assumed		(23,040)
Total purchase price	$	128,217

Pro Forma Information


	Twelve Months Ended
	December 31,
	2016		2015
Total revenues	$	182,007	$	179,266
Net income (loss)		17,692		(4,787)

Pro forma income (loss) per common share - basic	$	0.54	$	(0.15)
Pro forma income (loss) per common share - diluted	$	0.53	$	(0.15)

Inventories And Deferred Preservation Costs (Tables)

9 Months Ended

Sep. 30, 2017

Inventories And Deferred Preservation Costs [Abstract]

Schedule Of Inventories


	September 30,		December 31,
	2017		2016
Raw materials and supplies	$	11,153	$	9,321
Work-in-process		4,028		3,321
Finished goods		12,582		13,651
Total inventories	$	27,763	$	26,293

Schedule Of Deferred Preservation Costs


	September 30,		December 31,
	2017		2016
Cardiac tissues	$	17,195	$	15,768
Vascular tissues		17,813		14,920
Total deferred preservation costs	$	35,008	$	30,688

Goodwill And Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2017

Goodwill And Other Intangible Assets [Abstract]

Schedule Of Carrying Values Of Indefinite Lived Intangible Assets


	September 30,		December 31,
	2017		2016
Goodwill	$	78,294	$	78,294
Procurement contracts and agreements		2,013		2,013
Trademarks		841		841

Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Period Of Definite Lived Intangible Assets


	Gross Carrying		Accumulated		Amortization
September 30, 2017	Value		Amortization		Period
Acquired technology	$	38,478	$	7,615	11	–	22	Years
Patents		3,593		2,766			17	Years
Distribution and manufacturing rights and know-how		4,059		1,748	11	–	15	Years
Customer lists and relationships		29,140		3,190	13	–	22	Years
Other		1,418		942			3	Years

	Gross Carrying		Accumulated		Amortization
December 31, 2016	Value		Amortization		Period
Acquired technology	$	38,478	$	5,956	11	–	22	Years
Patents		3,710		2,702			17	Years
Distribution and manufacturing rights and know-how		4,059		1,532	11	–	15	Years
Customer lists and relationships		29,140		2,141	13	–	22	Years
Non-compete agreement		381		381			10	Years
Other		1,262		531			3	Years

Summary Of Amortization Expense


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Amortization expense	$	1,140	$	1,155	$	3,423	$	3,273

Scheduled Amortization Of Intangible Assets For Next Five Years


	Remainder
	of 2017		2018		2019		2020		2021		2022
Amortization expense	$	1,140	$	4,444	$	4,102	$	3,939	$	3,918	$	3,390

Debt (Tables)

9 Months Ended

Sep. 30, 2017

Debt [Abstract]

Schedule Of Short-Term And Long-Term Balances Of Term Loan


	September 30,		December 31,
	2017		2016
Term loan balance	$	69,678	$	73,594
Less unamortized loan origination costs		(1,609)		(2,020)
Net borrowings		68,069		71,574
Less short-term loan balance		(3,234)		(4,562)
Long-term loan balance	$	64,835	$	67,012

Stock Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Stock Compensation [Abstract]

Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options


	Three Months Ended				Nine Months Ended
	September 30, 2017				September 30, 2017
	Stock Options		ESPP Options		Stock Options		ESPP Options
Expected life of options		N/A		0.5 Years		4.8 Years		0.5 Years
Expected stock price volatility		N/A		0.43		0.40		0.35
Risk-free interest rate		N/A		1.14%		1.87%		0.62%


	Three Months Ended				Nine Months Ended
	September 30, 2016				September 30, 2016
	Stock Options		ESPP Options		Stock Options		ESPP Options
Expected life of options		4.8 Years		0.5 Years		4.8 Years		0.5 Years
Expected stock price volatility		0.40		0.30		0.40		0.30
Risk-free interest rate		1.19%		0.49%		1.20%		0.49%

Summary Of Total Stock Compensation Expenses


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
RSA, PSA, RSU, and PSU expense	$	1,448	$	1,397	$	4,326	$	3,616
Stock option and ESPP option expense		519		421		1,614		1,203
Total stock compensation expense	$	1,967	$	1,818	$	5,940	$	4,819

Income Per Common Share (Tables)

9 Months Ended

Sep. 30, 2017

Income Per Common Share [Abstract]

Computation Of Basic And Diluted Income Per Common Share


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
Basic income per common share	2017		2016		2017		2016
Net income	$	1,325	$	2,993	$	6,711	$	7,881
Net income allocated to participating securities		(22)		(58)		(126)		(152)
Net income allocated to common shareholders	$	1,303	$	2,935	$	6,585	$	7,729

Basic weighted-average common shares outstanding		32,887		32,151		32,665		31,731
Basic income per common share	$	0.04	$	0.09	$	0.20	$	0.24

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
Diluted income per common share	2017		2016		2017		2016
Net income	$	1,325	$	2,993	$	6,711	$	7,881
Net income allocated to participating securities		(22)		(56)		(122)		(148)
Net income allocated to common shareholders	$	1,303	$	2,937	$	6,589	$	7,733

Basic weighted-average common shares outstanding		32,887		32,151		32,665		31,731
Effect of dilutive stock options and awardsa		1,170		1,014		1,186		837
Diluted weighted-average common shares outstanding		34,057		33,165		33,851		32,568
Diluted income per common share	$	0.04	$	0.09	$	0.19	$	0.24

___________________

Segment Information (Tables)

9 Months Ended

Sep. 30, 2017

Segment Information [Abstract]

Revenues, Cost Of Products And Services, And Gross Margins For Operating Segments


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Revenues:
Medical devices	$	27,029	$	28,004	$	84,519	$	85,067
Preservation services		16,970		17,248		52,357		50,284
Total revenues		43,999		45,252		136,876		135,351

Cost of products and preservation services:
Medical devices		6,220		6,598		21,196		21,299
Preservation services		7,917		8,872		23,401		26,348
Total cost of products and preservation services		14,137		15,470		44,597		47,647

Gross margin:
Medical devices		20,809		21,406		63,323		63,768
Preservation services		9,053		8,376		28,956		23,936
Total gross margin	$	29,862	$	29,782	$	92,279	$	87,704

Summary Of Net Revenues By Product And Service


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Products:
BioGlue and BioFoam	$	15,730	$	15,976	$	48,094	$	47,479
On-X		8,326		8,890		27,048		25,159
CardioGenesis cardiac laser therapy		1,489		1,653		5,130		5,497
PerClot		886		950		2,641		2,983
PhotoFix		598		535		1,606		1,406
HeRO Graft		--		--		--		2,325
ProCol		--		--		--		218
Total products		27,029		28,004		84,519		85,067

Preservation services:
Cardiac tissue		7,932		8,279		23,911		22,255
Vascular tissue		9,038		8,969		28,446		28,029
Total preservation services		16,970		17,248		52,357		50,284

Total revenues	$	43,999	$	45,252	$	136,876	$	135,351

Basis Of Presentation (Narrative) (Details) - Accounting Standards Update 2016-09 [Member] - Impact Of Forfeitures On Compensation Cost [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2017 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase to additional paid in capital	$ 379
Increase to deferred tax assets	141
Deferred Tax Assets [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment	(141)
Retained Earnings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment	(238)
Additional Paid In Capital [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment	$ 379

Financial Instruments (Summary Of Financial Instruments Measured At Fair Value) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	$ 1,142	$ 4,165
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	371	3,466
Restricted securities	771	699
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	1,142	4,165
Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	371	3,466
Restricted securities	771	699
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets
Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents
Restricted securities
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets
Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents
Restricted securities

Cash Equivalents And Restricted Securities (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	$ 771		$ 771		$ 699
Gross realized gains or losses on cash equivalents	0	$ 0	0	$ 0
Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	771		771		699
Maturity Date Within Three Months [Member] \| Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	235		235		490
Maturity Date Between Three Months And One Year [Member] \| Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities	$ 536		$ 536		$ 209
Minimum [Member] \| Maturity Date Between Three Months And One Year [Member] \| Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period			3 months		3 months
Maximum [Member] \| Maturity Date Within Three Months [Member] \| Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period			3 months		3 months
Maximum [Member] \| Maturity Date Between Three Months And One Year [Member] \| Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted securities maturity period			1 year		1 year

Cash Equivalents And Restricted Securities (Summary Of Cash Equivalents And Restricted Securities) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Cash and Cash Equivalents [Line Items]
Cash Equivalents, Cost Basis	$ 54,242	$ 56,642	$ 54,131	$ 37,588
Restricted Securities, Cost Basis	771	699
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash Equivalents, Cost Basis	371	3,466
Restricted Securities, Cost Basis	771	699
Unrealized Holding Gains
Cash Equivalents, Estimated Market Value	371	3,466
Restricted Securities, Estimated Market Value	$ 771	$ 699

Acquisition Of On-X Life Technologies (Narrative) (Details) - On-X Agreement [Member] - USD ($) $ in Thousands			9 Months Ended		11 Months Ended
	Jan. 20, 2016	Dec. 22, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Agreement date			Dec. 22, 2015
Acquisition price	$ 128,200
Close date			Jan. 20, 2016
Total purchase price	128,217
Cash consideration	$ 93,600
Common shares issued	3,703,699
Common stock consideration	$ 34,600
Transaction and integration costs					$ 7,400
Escrow deposit, part of payments to acquire business	$ 10,000
Revenues					$ 34,200
Pro forma tax rate			38.00%	38.00%
Plan [Member]
Business Acquisition [Line Items]
Acquisition price		$ 130,000

Acquisition Of On-X Life Technologies (Purchase Price Allocation) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Jan. 20, 2016
Business Acquisition [Line Items]
Goodwill	$ 78,294	$ 78,294
On-X Agreement [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			$ 2,472
Receivables			6,826
Inventories			12,889
Intangible assets			53,950
Goodwill			68,229
Other assets			6,891
Liabilities assumed			(23,040)
Total purchase price			$ 128,217

Acquisition Of On-X Life Technologies (Pro Forma Information) (Details) - On-X Agreement [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Total revenues	$ 182,007	$ 179,266
Net income (loss)	$ 17,692	$ (4,787)
Pro forma income (loss) per common share - basic	$ 0.54	$ (0.15)
Pro forma income (loss) per common share - diluted	$ 0.53	$ (0.15)

Sales Of Business Components (Narrative) (Details) - USD ($) $ in Thousands			3 Months Ended	9 Months Ended		12 Months Ended
	Mar. 18, 2016	Feb. 03, 2016	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of business				$ 740	$ 19,795
Hancock Jaffe [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution agreement amount of payment				$ 3,400
Inventory received	$ 1,700
HeRO Graft Product Line [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amount of consideration received from sale of product line		$ 18,500
Proceeds from divestiture of business			$ 740			$ 17,800
Pre-tax gain (loss) on sale business components		$ 8,800
ProCol [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of business	2,000
Pre-tax gain (loss) on sale business components	(845)
Remaining prepayments settled	$ 1,700
HeRO Graft And ProCol Product Lines [Member] \| Maximum [Member] \| Product Lines Concentration Risk [Member] \| Total Revenues [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration percentage							10.00%
HeRO Graft And ProCol Product Lines [Member] \| Maximum [Member] \| Product Lines Concentration Risk [Member] \| Long-Lived Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration percentage							10.00%

PhotoFix Distribution Agreement And Acquisition (Narrative) (Details) - GBI Agreement [Member] $ in Thousands		9 Months Ended
	Apr. 13, 2016 USD ($)	Sep. 30, 2017 item
Initial term of contract for distribution rights		5 years
Number of contract renewals \| item		2
Term of contract renewals		1 year
Close date		Apr. 13, 2016
Total purchase price	$ 2,300
Cash consideration	1,200
Advance consideration	600
Payment after successful transfer	$ 400

Inventories And Deferred Preservation Costs (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Inventory [Line Items]
Consignment inventory	$ 5.8	$ 4.9
Domestic [Member]
Inventory [Line Items]
Consignment inventory percentage	85.00%	80.00%
Foreign [Member]
Inventory [Line Items]
Consignment inventory percentage	15.00%	20.00%

Inventories And Deferred Preservation Costs (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventories And Deferred Preservation Costs [Abstract]
Raw materials and supplies	$ 11,153	$ 9,321
Work-in-process	4,028	3,321
Finished goods	12,582	13,651
Total inventories	$ 27,763	$ 26,293

Inventories And Deferred Preservation Costs (Schedule Of Deferred Preservation Costs) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Total deferred preservation costs	$ 35,008	$ 30,688
Cardiac Tissues [Member]
Total deferred preservation costs	17,195	15,768
Vascular Tissues [Member]
Total deferred preservation costs	$ 17,813	$ 14,920

Goodwill And Other Intangible Assets (Schedule Of Carrying Values Of Indefinite Lived Intangible Assets)(Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 78,294	$ 78,294
Procurement Contracts And Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	2,013	2,013
Trademarks [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	$ 841	$ 841

Goodwill And Other Intangible Assets (Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Period Of Definite Lived Intangible Assets) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 38,478	$ 38,478
Accumulated amortization	7,615	5,956
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3,593	3,710
Accumulated amortization	2,766	2,702
Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,059	4,059
Accumulated amortization	1,748	1,532
Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	29,140	29,140
Accumulated amortization	3,190	2,141
Non-Compete Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value		381
Accumulated amortization		381
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,418	1,262
Accumulated amortization	$ 942	$ 531
Minimum [Member] \| Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] \| Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] \| Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	13 years	13 years
Maximum [Member] \| Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	22 years	22 years
Maximum [Member] \| Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	17 years	17 years
Maximum [Member] \| Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	15 years	15 years
Maximum [Member] \| Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	22 years	22 years
Maximum [Member] \| Non-Compete Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period		10 years
Maximum [Member] \| Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	3 years	3 years

Goodwill And Other Intangible Assets (Summary Of Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Goodwill And Other Intangible Assets [Abstract]
Amortization expense	$ 1,140	$ 1,155	$ 3,423	$ 3,273

Goodwill And Other Intangible Assets (Scheduled Amortization Of Intangible Assets For Next Five Years) (Details) $ in Thousands	Sep. 30, 2017 USD ($)
Goodwill And Other Intangible Assets [Abstract]
Remainder of 2017	$ 1,140
2018	4,444
2019	4,102
2020	3,939
2021	3,918
2022	$ 3,390

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Income Taxes [Abstract]
Effective income tax rate		37.00%		46.00%
Provision to return adjustments	$ 1,100		$ 2,700
Valuation allowances against deferred tax assets	1,800		1,800		$ 2,200
Net deferred tax asset	$ 1,200		$ 1,200
Net deferred tax liability					$ 7

Debt (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Debt (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Line of Credit Facility [Line Items]
Term loan balance	$ 69,678		$ 69,678		$ 73,594
Interest expense	851	$ 742	2,500	$ 2,300
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Credit facility outstanding balance	0		0		0
Credit facility remaining availability	20,000		$ 20,000		$ 20,000
Revolving Credit Facility [Member] \| On-X Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility commitment fee percentage			0.50%
Revolving Credit Facility [Member] \| On-X Agreement [Member] \| Amended Debt Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate commitments	20,000		$ 20,000
Senior Secured Credit Facility [Member] \| On-X Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate commitments	$ 95,000		$ 95,000
Credit facility aggregate interest rate	3.99%		3.99%
Credit facility default interest rate	2.00%		2.00%
Senior Secured Credit Facility [Member] \| Minimum [Member] \| On-X Agreement [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin			1.75%
Senior Secured Credit Facility [Member] \| Minimum [Member] \| On-X Agreement [Member] \| LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility margin			2.75%
Senior Secured Credit Facility [Member] \| Maximum [Member] \| On-X Agreement [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin			2.75%
Senior Secured Credit Facility [Member] \| Maximum [Member] \| On-X Agreement [Member] \| LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility margin			3.75%
Term Loan [Member] \| On-X Agreement [Member]
Line of Credit Facility [Line Items]
Term loan balance	$ 75,000		$ 75,000
Credit facility maturity date			Jan. 20, 2021
Letter Of Credit Sub-Facility [Member] \| On-X Agreement [Member] \| Amended Debt Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate commitments	4,000		$ 4,000
Swing-Line Sub-Facility [Member] \| On-X Agreement [Member] \| Amended Debt Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility aggregate commitments	$ 3,000		$ 3,000
Swing-Line Sub-Facility [Member] \| Minimum [Member] \| On-X Agreement [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin			1.75%
Swing-Line Sub-Facility [Member] \| Maximum [Member] \| On-X Agreement [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility margin			2.75%

Debt (Schedule Of Short-Term And Long-Term Balances Of Term Loan) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Debt [Abstract]
Term loan balance	$ 69,678	$ 73,594
Less unamortized loan origination costs	(1,609)	(2,020)
Net borrowings	68,069	71,574
Less short-term loan balance	(3,234)	(4,562)
Long-term loan balance	$ 64,835	$ 67,012

Commitments And Contingencies (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Other Commitments [Line Items]
Unreported loss liability	$ 1,600	$ 1,500
Recoverable insurance amounts	716	626
Property and equipment, net	20,607	$ 18,502
PerClot [Member]
Other Commitments [Line Items]
Prepaid royalties	1,500
Net intangible assets	2,700
Property and equipment, net	1,400
Maximum [Member]
Other Commitments [Line Items]
Estimated loss	$ 3,000
Starch Technology Purchase [Member]
Other Commitments [Line Items]
Term of distribution agreement	15 years
Expected future contingent payment amounts	$ 1,000
Number of notice days	180 days

Shareholders' Equity (Narrative) (Details) - USD ($) $ in Thousands	Jan. 20, 2016	Sep. 30, 2017
Retained Earnings [Member] \| Accounting Standards Update 2016-09 [Member] \| Impact Of Forfeitures On Compensation Cost [Member]
Equity, Class of Treasury Stock [Line Items]
Cumulative-effect adjustment		$ (238)
Additional Paid In Capital [Member] \| Accounting Standards Update 2016-09 [Member] \| Impact Of Forfeitures On Compensation Cost [Member]
Equity, Class of Treasury Stock [Line Items]
Cumulative-effect adjustment		379
On-X Agreement [Member]
Equity, Class of Treasury Stock [Line Items]
Common shares issued	3,703,699
Common stock value issued in business combination	$ 34,600
Deferred Tax Assets [Member] \| Accounting Standards Update 2016-09 [Member] \| Impact Of Forfeitures On Compensation Cost [Member]
Equity, Class of Treasury Stock [Line Items]
Cumulative-effect adjustment		$ (141)

Stock Compensation (Narrative) (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees purchased common stock, shares	47	52	93	90
Capitalized stock compensation expense	$ 111	$ 70	$ 288	$ 202
ESPP Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, percentage of market price for eligible employees			85.00%
RSAs, RSUs, And PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized awards from approved stock incentive plans			384	478
Aggregate grant date market value			$ 6,300	$ 5,300
Unrecognized compensation costs	6,800		6,800
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs	$ 2,100		$ 2,100
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year 8 months 12 days
Restricted Stock Awards (RSAs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year 3 months 18 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			2 years 1 month 6 days
Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units					142.00%
Expected weighted-average period for recognizing the unrecognized compensation costs, in years			1 year
Minimum [Member] \| Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units			60.00%	60.00%
Maximum [Member] \| Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units			150.00%	150.00%
Officers [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants of stock options			260	387

Stock Compensation (Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options		4 years 9 months 18 days	4 years 9 months 18 days	4 years 9 months 18 days
Expected stock price volatility		0.40%	0.40%	0.40%
Risk-free interest rate		1.19%	1.87%	1.20%
ESPP Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	6 months	6 months	6 months	6 months
Expected stock price volatility	0.43%	0.30%	0.35%	0.30%
Risk-free interest rate	1.14%	0.49%	0.62%	0.49%

Stock Compensation (Summary Of Total Stock Compensation Expenses) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 1,967	$ 1,818	$ 5,940	$ 4,819
RSA, PSA, RSU, And PSU Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	1,448	1,397	4,326	3,616
Stock Option And ESPP Option Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 519	$ 421	$ 1,614	$ 1,203

Income Per Common Share (Computation Of Basic And Diluted Income Per Common Share) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Net income

$ 1,325

$ 2,993

$ 6,711

$ 7,881

Net income allocated to participating securities

(22)

(58)

(126)

(152)

Net income allocated to common shareholders

$ 1,303

$ 2,935

$ 6,585

$ 7,729

Basic weighted-average common shares outstanding

32,887

32,151

32,665

31,731

Basic income per common share

$ 0.04

$ 0.09

$ 0.20

$ 0.24

Net income allocated to participating securities, diluted

$ (22)

$ (56)

$ (122)

$ (148)

Net income allocated to common shareholders, diluted

$ 1,303

$ 2,937

$ 6,589

$ 7,733

Effect of dilutive stock options and awards

^[1]

1,170

1,014

1,186

837

Diluted weighted-average common shares outstanding

34,057

33,165

33,851

32,568

Diluted income per common share

$ 0.04

$ 0.09

$ 0.19

$ 0.24

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share

264

215

810

[1]

We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to income per common share. Accordingly, stock options to purchase a weighted-average 264,000 and 215,000 shares for the three and nine months ended September 30, 2017, respectively, and 1,000 and 810,000 shares for the three and nine months ended September 30, 2016, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.

Segment Information (Revenues, Cost Of Products And Services, And Gross Margins For Operating Segments) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) segment	Sep. 30, 2016 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| segment			2
Total revenues	$ 43,999	$ 45,252	$ 136,876	$ 135,351
Total cost of products and preservation services	14,137	15,470	44,597	47,647
Total gross margin	29,862	29,782	92,279	87,704
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Total revenues			0
Operating Segments [Member] \| Medical Devices [Member]
Segment Reporting Information [Line Items]
Total revenues	27,029	28,004	84,519	85,067
Total cost of products and preservation services	6,220	6,598	21,196	21,299
Total gross margin	20,809	21,406	63,323	63,768
Operating Segments [Member] \| Preservation Services [Member]
Segment Reporting Information [Line Items]
Total revenues	16,970	17,248	52,357	50,284
Total cost of products and preservation services	7,917	8,872	23,401	26,348
Total gross margin	$ 9,053	$ 8,376	$ 28,956	$ 23,936

Segment Information (Summary Of Net Revenues By Product And Service) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Product Information [Line Items]
Total revenues	$ 43,999	$ 45,252	$ 136,876	$ 135,351
BioGlue And BioFoam [Member]
Product Information [Line Items]
Total revenues	15,730	15,976	48,094	47,479
On-X [Member]
Product Information [Line Items]
Total revenues	8,326	8,890	27,048	25,159
CardioGenesis Cardiac Laser Therapy [Member]
Product Information [Line Items]
Total revenues	1,489	1,653	5,130	5,497
PerClot [Member]
Product Information [Line Items]
Total revenues	886	950	2,641	2,983
PhotoFix [Member]
Product Information [Line Items]
Total revenues	598	535	1,606	1,406
HeRO Graft [Member]
Product Information [Line Items]
Total revenues				2,325
ProCol [Member]
Product Information [Line Items]
Total revenues				218
Cardiac Tissues [Member]
Product Information [Line Items]
Total revenues	7,932	8,279	23,911	22,255
Vascular Tissues [Member]
Product Information [Line Items]
Total revenues	9,038	8,969	28,446	28,029
Operating Segments [Member] \| Total Products [Member]
Product Information [Line Items]
Total revenues	27,029	28,004	84,519	85,067
Operating Segments [Member] \| Total Preservation Services [Member]
Product Information [Line Items]
Total revenues	$ 16,970	$ 17,248	$ 52,357	$ 50,284

JOTEC Acquisition (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended
	Nov. 30, 2017	Oct. 10, 2017	Sep. 30, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Term loan balance			$ 69,678	$ 73,594
Scenario, Forecast [Member] \| JOTEC AG [Member]
Subsequent Event [Line Items]
Acquisition price	$ 225,000
Percent of payments to acquire business that is cash	75.00%
Percent of payments to acquire business that is in common stock issued	25.00%
Scenario, Forecast [Member] \| JOTEC AG [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Common stock value issued in business combination	$ 56,250
Term Loan [Member] \| Subsequent Event [Member] \| JOTEC AG [Member]
Subsequent Event [Line Items]
Term loan balance		$ 69,000
Senior Secured Credit Facility [Member] \| Scenario, Forecast [Member] \| JOTEC AG [Member]
Subsequent Event [Line Items]
Financing for business acquisition	255,000
Term Loan B [Member] \| Scenario, Forecast [Member] \| JOTEC AG [Member]
Subsequent Event [Line Items]
Financing for business acquisition	225,000
Revolving Credit Facility [Member] \| Scenario, Forecast [Member] \| JOTEC AG [Member]
Subsequent Event [Line Items]
Financing for business acquisition	$ 30,000